secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K/A
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001683168-24-004772
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma regains Nasdaq bid price compliance; still faces equity rule delisting risk
--------------------------------------------------------------------------------

- Received Nasdaq letter on July 5, 2024 confirming bid price compliance (closing bid >=$1.00 for 20 consecutive business days through July 3).
- Previously granted extension until July 15, 2024 to demonstrate compliance with both Bid Price and Equity Rules.
- Company still not compliant with $2,500,000 stockholders' equity requirement (Nasdaq Listing Rule 5550(b)); further updates expected.
- Delisting risk remains if equity compliance not demonstrated by deadline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824004772/0001683168-24-004772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824004772/cns_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-004772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer